Figure S1 from Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Year: 2023
Type: other
Abstract: Supplemental Figure 1. (A) KIT mutational status of the cohort; (B) Prevalence of CBF subtype among the E8 and E17 mutations. (B) Among E8 mutations, 54% of patients were inv(16) and 46% were t(8;21). (C) Among E17 mutations, 37% of patients were inv(16) and 63% were t(8;21).
Authors: Katherine Tarlock, Todd A. Alonzo, Yi-Cheng Wang, Robert B. Gerbing, Rhonda Ries, Michael R. Loken, Laura Pardo, Tiffany Hylkema, Jason Joaquin, Leela Sarukkai, Susana C. Raimondi, Betsy Hirsch, Lillian Sung, Richard Aplenc, Irwin Bernstein, Alan S. Gamis, Soheil Meshinchi, Jessica A. Pollard
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361936156